MediWound reports Q1 EPS (7c), consensus (66c)

Reports Q1 revenue $4M, consensus $5.2M. “We entered 2025 with strong execution across our clinical, commercial, and operational priorities, maintaining the momentum established in 2024,” said Ofer Gonen, Chief Executive Officer of MediWound (MDWD). “The VALUE Phase III study for EscharEx remains on schedule, and our additional collaboration with Kerecis marks a significant milestone-bringing nearly all leading global wound care companies into our clinical research programs. Meanwhile, NexoBrid continues to gain global traction, as we advance strategic manufacturing investments to support sustained, long-term growth.”